Meta Description: A clinical trial evaluates Pistacia lentiscus oil nasal drops for preventing chronic rhinosinusitis recurrence. Results may impact treatment options for this condition.
A recently completed clinical trial has investigated Pistacia lentiscus oil nasal drops (Bactorinol®) as a preventive measure for recurrence of chronic rhinosinusitis without nasal polyps. The study, conducted collaboratively by Liaquat University of Medical & Health Sciences and Università degli Studi dell’Insubria, offers new insights for healthcare professionals specializing in otolaryngology. Completed as of October 1, 2025, this research provides evidence-based data on an alternative treatment to manage this persistent condition.
In this article:
- What was the purpose of the study?
- What are the key findings?
- What are the clinical and regulatory implications?
- FAQs
- Conclusion
- Disclaimer
- Full study announcement
What was the purpose of the study?
The trial aimed to evaluate the efficacy of Pistacia lentiscus oil nasal drops (Bactorinol®) in preventing the recurrence of chronic rhinosinusitis without nasal polyps. A placebo-controlled design was adopted for systematic evaluation. This condition often leads to a significant impact on patients’ quality of life, creating a need for reliable interventions to prevent its recurrence.
Why Pistacia lentiscus oil?
Pistacia lentiscus oil has antimicrobial and anti-inflammatory properties. These characteristics make it a candidate for addressing the causes of chronic rhinosinusitis, such as bacterial colonization and persistent inflammation. The trial included a matched placebo group to ensure the validity of the findings.
What are the key findings?
Although specific data from the study has not been disclosed in the source material, the completion of the clinical trial indicates that it has generated results for review. The involvement of prominent institutions underscores the potential reliability and clinical value of the outcomes.
Further information is awaited on patient response, tolerance to the nasal drops, and detailed comparative analysis between Bactorinol® and the placebo.
Potential breakthroughs
If Bactorinol® proves effective, healthcare providers may have another tool to reduce the recurrence of chronic rhinosinusitis. As recurrence often brings significant healthcare costs and patient discomfort, these findings could offer timely solutions for addressing unmet clinical needs.
What are the clinical and regulatory implications?
Clinicians treating rhinosinusitis may soon benefit from additional therapy options. If further data supports efficacy, Pistacia lentiscus oil nasal drops could reduce dependency on other treatments like antibiotics or corticosteroids, which carry their own risks.
From a regulatory perspective, the successful completion of a controlled clinical trial is essential for pathway approvals under frameworks like the Medical Device Regulation (MDR) in the EU. Verification of the drops’ safety, performance, and intended use will remain pivotal in determining market availability.
Next steps
Predicting regulatory submissions or market entry remains speculative until the study results are published. Stakeholders may anticipate follow-up studies, peer-reviewed publications, or regulatory filings to explore the full clinical potential of this approach.
Frequently Asked Questions
1. What is chronic rhinosinusitis?
Chronic rhinosinusitis is a long-term inflammation of the sinuses, potentially caused by infections, allergies, or environmental factors. It significantly affects quality of life.
2. How does Pistacia lentiscus oil work?
The oil has documented antimicrobial and anti-inflammatory properties, making it suitable for tackling infection and inflammation associated with rhinosinusitis.
3. Is Bactorinol® already available in the market?
Bactorinol®’s availability will depend on further regulatory approvals following the completed study results.
Conclusion
The completion of this trial represents an important step for developing alternative treatments for chronic rhinosinusitis. While we await detailed results, the findings could shape the future of clinical strategies aimed at reducing recurrence.
Disclaimer
This article is intended for healthcare professionals and regulatory teams. It is informational and does not constitute legal or clinical advice.
Full study announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07198607?term=medical+device